Deal Details
Enliven Completes $460.0 Million Follow-On Offering
Summary
Enliven Therapeutics, Inc. (“Enliven”) (NASDAQ: ELVN) recently completed the pricing of an upsized underwritten public offering (the “Offering”) of 10,533,334 shares of its common stock, including 1,600,000 shares sold pursuant to full exercise of the underwriters’ option to purchase additional shares, at a price of $37.50 per share and 1,733,333 pre-funded warrants at a price of $37.499 per pre-funded warrant, generating gross proceeds of approximately $460.0 million.
Baird served as lead manager on this Offering.
About
Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision medicine approach that improves survival and enhances overall well-being. Enliven's discovery process combines deep insights in clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is headquartered in Burlingame, California.CONTACT US TO LEARN MORE
- Date
- June 2026
- Company
- Enliven Therapeutics, Inc.
- Transaction
- Equity Capital Markets
- Sectors
- Healthcare
- Verticals
-
Biotechnology & Pharmaceuticals
- Target Geography
- North America
Share
